JP4805589B2 - Estrogenic agent - Google Patents

Description

  The present invention relates to an estrogenic agent. More specifically, the present invention relates to an estrogen-like agent composed of an essential oil having an estrogenic action, a skin external preparation containing the same, sundry goods, clothing or food, and a cosmetic method using the essential oil having an estrogenic action.

  Estrogen (follicular hormone) is a kind of female hormone, and is used as a general term for hormones that exhibit estrus and similar substances. As natural estrogens, estrone, estradiol, estriol and the like are known, and estradiol is the main one. Synthetic estrogens having biological activities equivalent to those are also known.

  Estrogens are mainly secreted from the ovarian follicles and corpus luteum, but also from the fetal placenta, adrenal gland, and ovaries during pregnancy. Estrogen secretion from the ovaries is feedback-regulated through the hypothalamus and anterior pituitary gland of the brain, thus establishing the estrous cycle. Estrogens act via their receptors, and have receptors in various tissues as well as the target tissues, genital organs and mammary glands, and their effects are systemic. Thus, estrogens not only affect reproductive function, but also affect the brain, cardiovascular, skeletal, skin, and other tissues and are deeply involved in the health of adult women. The main physiological effects of estrogen include endometrial proliferation, myometrial development, expression of secondary sexual characteristics, mediation of menstrual cycle, induction of maternal changes during pregnancy, and promotion of growth secretion of mammary ducts It is done. Also in men, estrogen receptors exist in the brain, cardiovascular, skeletal, skin, and other tissues, and estrogen converted from male hormone (testosterone) acts by the action of the metabolic enzyme aromatase. Therefore, estrogen is deeply related to health in men.

  Lack of estrogen secretion or hormonal imbalance has a particularly prominent effect in women, leading to premenstrual syndrome (PMS), menstrual abnormalities, menopause, etc., and the loss of endogenous estrogen continues. It is said to cause sexual decline, sexual pain and urinary incontinence due to urogenital atrophy, hyperlipidemia (change in lipid metabolism), osteoporosis and the like. Moreover, among women in their 20s and 40s, hormonal balance is disrupted due to excessive stress and diet associated with social advancement, and juvenile climacteric disorders exhibiting symptoms similar to climacteric disorders are increasing. Thus, lack of estrogen secretion or hormonal imbalance has become a very serious problem in improving the quality of life (QOL) of women.

  Treatment of symptoms associated with lack of estrogen secretion such as PMS and climacteric disorder or hormonal imbalance, treatment with diuretics, tranquilizers, analgesics, vitamins, etc., and hormones such as estrogen agonists It is performed by hormone replacement therapy that is administered directly.

  However, hormonal therapy is very difficult to adjust, and also adversely affects other hormones, which may disturb the homeostasis. In addition, currently used estrogen agonists are known to have side effects such as gastrointestinal disorders, thrombosis, uterine bleeding, liver disorders, and uterine cancer and breast cancer may occur when administered for a long time. It is known.

  In recent years, various attempts have been made to adjust female hormone balance using extracts of animals and plants having an estrogen-like action (for example, Patent Documents 1 to 3), but the estrogen-like action caused by essential oils (fragrances) has been completely reported. Not.

In aroma therapy (aromatherapy), it is empirically known to relieve psychosomatic symptoms related to female hormones by inhaling aromatic substances such as fragrances. However, until now, studies on the influence of the fragrance of fragrances on endocrine have been mainly related to the effects on stress-related hormones such as cortisol, and little studies have been made on the effects of fragrances on sex hormones.
JP 2001-103931 A JP 2003-277274 A Japanese Patent Laid-Open No. 2004-15579

  In view of the circumstances as described above, the present invention prevents, ameliorates or treats various symptoms caused by insufficient estrogen secretion or hormonal imbalance such as climacteric disorder, juvenile climacteric disorder, premenstrual syndrome, etc. An object of the present invention is to provide an estrogen agonist that is highly safe and can be used for a long period of time.

  Another object of the present invention is to provide a cosmetic method for enhancing the estrogen-like action safely and easily.

  The present inventor has found that a specific essential oil has an estrogenic action, and has completed the present invention.

  The estrogenic agent of the present invention is characterized by comprising an essential oil selected from the group consisting of thyme oil, geranium oil, clary sage oil, near uri oil and rose oil.

  Further, the beauty method of the present invention, by smelling the scent of essential oil selected from the group consisting of thyme oil, geranium oil, clary sage oil, near uri oil and rose oil, or by applying the essential oil to the skin, It is characterized by enhancing the estrogen-like action.

  The estrogen-like agent and cosmetic method of the present invention should be used effectively in the prevention, improvement or treatment of symptoms caused by insufficient estrogen secretion or hormonal imbalance such as menopause, juvenile menopause or premenstrual syndrome. Can do. In addition, the estrogenic agent of the present invention or the essential oil used in the cosmetic method can be used by blending with any product such as a skin external preparation, miscellaneous goods, clothing or food.

  Here, “estrogen-like action” refers to various physiological actions of estrogen through binding to estrogen receptors (eg, endometrial proliferation, myometrial development, mediation of establishment of menstrual cycle, pregnancy Induction of maternal changes, promotion of growth and secretion of mammary ducts, control of nerve activity in the brain, lipid metabolism in liver and adipose tissue, bone metabolism in osteoblasts and osteoclasts, etc. means.

  The present invention relates to symptoms associated with general malaise and indefinite complaints such as climacteric disorder, juvenile climacteric disorder, menstrual abnormalities, and premenstrual syndrome caused by estrogen deficiency and hormonal abnormalities by using an essential oil having an estrogenic effect. In addition, various symptoms such as sexual pain, urinary incontinence, and osteoporosis due to skin elasticity reduction, genitourinary atrophy can be improved safely and easily. In particular, since the estrogen-like agent of the present invention is a volatile essential oil, it has good permeability to cell tissues from its lipophilicity, and absorbs when applied to the skin or ingested or inhaled essential oil components. Are better. Moreover, estrogen can be adjusted by making use of volatility and smelling the scent, and application to various aspects and product forms is possible. That is, by inhaling essential oil components vaporized by various methods, or by exposing the body to the vaporized fragrance components, the fragrance components can be absorbed minutely from the respiratory mucosa or skin. Therefore, a milder effect can be expected as compared with internal use, and adverse effects such as side effects due to overdose, which have been a problem in conventional hormone replacement therapy, can be avoided. In addition, since it can be administered without being conscious of taking such as time and frequency, it is possible to prevent forgetting to take, etc., and to provide a method suitable for hormone replacement therapy that requires long-term continuous use. it can.

  The thyme oil, geranium oil, rose oil, clary sage oil and near uri oil used in the present invention may be any of natural products, synthetic products, semi-synthetic products and the like. Such an essential oil can be prepared by any extraction method, distillation method, synthesis method, or the like, or a commercially available product may be used. In the present invention, the above essential oil can be used alone or in combination with one or more other essential oils. In addition, although all said essential oil is marketed, it demonstrates easily below.

As the thyme oil thyme oil, for example, an essential oil obtained by steam distillation of a raw grass of flowering thyme (Thymus vulgaris L.) or a dried one thereof can be used.

As the geranium oil , for example, an essential oil obtained by steam distillation of leaves and branches of the genus Pelargonium such as Pelargonium graveolens can be used.

Clarisage oil As the clary sage oil, for example, an essential oil obtained by steam distillation of flowering ears or whole plants of clam sage (Salvia sclarea L.) can be used.

As the near uri oil, for example, an essential oil obtained by steam distillation of the leaves and stems of Melarieuca viridiflora belonging to Myrtaceae can be used.

As the rose oil , for example, an essential oil obtained by steam distillation of a rose genus such as Rose damascena of the family Rosaceae can be used.

  The estrogenic agent composed of an essential oil having an estrogenic effect of the present invention is a symptom accompanied by general malaise and indefinite complaints such as menopause, juvenile climacteric disorder, menstrual abnormalities, premenstrual syndrome, and skin elasticity. It can be used for the prevention, amelioration, or treatment of any symptoms caused by estrogen deficiency or hormonal abnormalities such as sexual intercourse and urinary incontinence due to decrease, genitourinary atrophy, osteoporosis, prostatic hypertrophy, and prostate cancer.

  Here, “menopausal disorders” include general malaise, irritability, anxiety, depression, insomnia, dementia, memory loss and other neuropsychiatric symptoms, hot flashes, coldness, swelling, low back pain, tinnitus, stiff shoulders, increased heartbeat, Indefinite complaints such as abnormal sweating, as well as autonomic dysfunction, hyperlipidemia, arteriosclerosis, reduced skin collagen, wrinkles, dryness, atrophy, reduced skin elasticity, reduced skin wound healing ability, urogenital organs It refers to health disorders that occur in menopausal women, such as sexual pain, urinary incontinence, and osteoporosis due to atrophy.

  The term “juvenile climacteric disorder” refers to a mental or physical condition or disease that causes symptoms similar to climacteric disorders that occur in relatively young women in their 20s to 40s.

  “Premenstrual syndrome (PMS)” refers to a syndrome in which various symptoms appear periodically in the luteal phase after ovulation and disappear with the onset of menstruation or within 2 to 3 days. Refers to a syndrome mainly composed of mental symptoms such as agitation, depression, anxiety, headache, decreased motivation, sleepiness, and fatigue, breast tightness, breast pain, rough skin, stiff shoulders, and constipation. .

  The above essential oil having an estrogenic action may be used alone, but can be included in various objects. Depending on the type of the object, an optional component can be further included in addition to the above essential oil. Moreover, you may implement in the form which uses together the chemical | medical agent which has another estrogenic action, and the essential oil of this invention.

  For example, when the object is an external preparation for skin, its dosage form (for example, liquid, powder, granule, aerosol, solid, gel, patch, suppository, etc.) or product form (for example, Depending on cosmetics, pharmaceuticals, quasi-drugs, etc., any component usually contained in such an external preparation for skin may be included together with the essential oil having the estrogenic action. In the present specification, the term “skin external preparation” is a concept encompassing all compositions applied to the skin (including scalp, hair, and nails). For example, basic cosmetics, makeup cosmetics, hair cosmetics Cosmetics such as cosmetics, skin or hair cleansing agents, and various pharmaceuticals or quasi-drugs such as ointments, patches, suppositories, and toothpastes. The dosage form is also not particularly limited. For example, an aqueous solution system, a solubilization system, an emulsification system, an oil liquid system, a gel system, a paste system, an ointment system, an aerosol system, a water-oil two-layer system, a water-oil-powder 3 Includes any dosage form, such as a layer. Preferably, the external preparation for skin of the present invention is a cosmetic, such as perfume, eau de toilette, eau de cologne, cream, emulsions, lotion, foundations, powdered white powder, lipstick, soap, shampoo / rinse, body shampoo, body. Rinse, body powders, bath agents and the like can be mentioned.

  Also, for example, any miscellaneous goods such as fragrance, deodorant, aroma candle, incense, stationery, wallet, bag, shoes, etc., and any clothing such as underwear, clothes, hats, stockings, socks, etc. An essential oil having an estrogenic action can be contained in various forms of supplements (nutritional supplements) such as powders, granules, tablets, capsules, confectionery, beverages, and the like. The essential oil of the present invention may be added to those materials, or the essential oil of the present invention may be added to these products.

  Furthermore, as long as the effect of the present invention can be obtained, the above essential oil having an estrogen-like action may be used in an inhalation product such as an inhalation medicine.

  In addition, although the usage aspect of the essential oil which has the estrogen-like action of this invention was illustrated, it is not limited to these, As long as the effect of this invention can be achieved, it can be used in arbitrary aspects. In addition to the essential oil having an estrogenic action of the present invention, a general perfume component can be blended according to a specific embodiment as long as the effects of the present invention are not impaired.

  In addition, the blending amount of the essential oil having an estrogen-like action of the present invention in the object can be appropriately selected depending on the type and form of the essential oil to be used, the object and the like, and is not particularly limited. It is 0.0001-50 mass% with respect to the total mass of a target object, More preferably, it is 0.001-20 mass%, More preferably, it is 0.01-10 mass%.

  In the cosmetic method of the present invention, “to smell the scent of essential oil” means inhaling the vaporized essential oil component with breathing, or stimulating olfaction with the inhaled essential oil component, and its method and means are particularly limited. For example, the subject essential oil component or the external preparation containing the subject may be directly applied to the skin, or directly inhaled, or a fragrance, a deodorant, an aroma candle containing the subject essential oil component, Through any miscellaneous goods such as incense, stationery, wallet, bag, shoes, etc., any clothing such as underwear, clothes, hats, stockings, socks, etc., or any food such as supplements, confectionery, beverages, etc. You may smell the scent.

  The specific application of the cosmetic method of the present invention is not particularly limited as long as it relates to the enhancement of estrogen-like action.

  EXAMPLES Hereinafter, although an Example is given and this invention is demonstrated concretely, this invention is not limited to the following Example. In the examples, the essential oil manufactured by Bioland was used.

Evaluation of estrogen-like action MCF-7 cells are a human breast cancer-derived cell line, and their cell growth depends on estrogen. Therefore, they are used as a sensitive method for evaluating the estrogenic activity of various compounds in vitro. (For example, Okubo T et al. Biol Pharm Bull 26, 1219-1224 (2003), Diel P et al. Planta Med 65, 197-203 (1999)). Using these MCF-7 cells, the estrogen-like action of each essential oil was examined based on the following method. In addition, ethanol (0.1%) is used as a negative control, and estradiol (E2) (10 nM), which is a typical estrogen, and phytoestrogens (components having plant-derived estrogenic activity) as positive controls. Genistin (1 mM) and genistein (100 μM) were used. All essential oils were evaluated at a concentration of 0.01%.

Experimental Method MCF-7 cells were seeded in a 96-well plate and cultured in DMEM medium containing 10% FBS for 24 hours. Next, the medium was changed to a medium containing no phenol red and containing 5% of FBS from which hormone was completely removed by performing charcoal dextran treatment, and then each sample was added. After culturing for 6 days, the cells were collected and the number of viable cells was counted using Alama Blue. Each group was n = 4, and the average number of viable cells was used. The results were expressed as a ratio (relative%) of the number of living cells (average value) in each sample addition to the number of living cells (average value) when ethanol alone was added (negative control).

  The results are shown in FIG. Thyme oil, geranium oil, clary sage oil, near uri oil and rose oil showed an MCF-7 growth promoting effect equivalent to or higher than the positive controls estradiol, genistin and genistein at the evaluation concentrations. On the other hand, eucalyptus oil, pine needle oil, bergamot oil and cistus oil did not show any growth promoting effect on MCF-7 cells at the same concentration.

Confirmation of estrogen-like action using antagonistic inhibitors The growth-promoting effect of the above-mentioned thyme oil, geranium oil, clariage oil, near-uri oil and rose oil on MCF-7 cells is based on the estrogen-like action via estrogen receptor In order to confirm this, a competitive inhibition reaction test was performed using ICI182780 (manufactured by WAKO) which competitively inhibits the reaction between estrogen and the receptor. ICI182780 is an estrogen antagonist (competitive inhibitor) that has the same affinity as estrogen for the estrogen receptor, but does not have activity as an agonist (agonist). Therefore, if the effect of the drug is suppressed by the presence of ICI182780, it can be confirmed that the effect is mediated by the estrogen receptor and has an estrogenic action. On the other hand, if it is not suppressed, it can be inferred that the site of action of the drug is other than the estrogen receptor.

  In the same manner as described above, MCF-7 was cultured in a medium supplemented with 10 nM ICI182780 together with each essential oil (same concentration as above), and the number of viable cells was counted. The result was similarly expressed as a ratio (relative%) to the case where only ethanol was added.

  The results are shown in FIG. 2 (competitive inhibitor (+)). The growth-promoting effect of MCF-7 cells by thyme oil, geranium oil, clary sage oil, near uri oil and rose oil was inhibited by the addition of ICI182780, an estrogen receptor antagonist, as well as estradiol, genistin and genistein. It was. Because ICI182780 itself does not cytotoxically affect MCF-7 cells at this added concentration, this growth inhibition is based on the antagonistic response of each essential oil and ICI182780 to the estrogen receptor. Therefore, it was confirmed that the effect of promoting the growth of MCF-7 cells by these essential oils was due to a female hormone-like action via the estrogen receptor.

  Hereinafter, formulation examples of typical product forms of external preparations for skin, miscellaneous goods, clothes or foods containing the estrogenic agent of the present invention are shown as examples. In any case, the essential oil of the present invention is one or a mixture of two or more selected from the group consisting of thyme oil, geranium oil, clary sage oil, near uri oil and rose oil. In addition, all compounding quantities are represented by the mass% with respect to the product whole quantity.

Example 1
Lotion (Formulation Example 1)
(1) Glycerin 2.0
(2) Dipropylene glycol 2.0
(3) PEG-60 hydrogenated castor oil 0.3
(4) Trimethylglycine 0.1
(5) Preservative appropriate amount (6) chelating agent appropriate amount (7) dye appropriate amount (8) essential oil of the present invention 0.05
(9) Purified water residue

Example 2
Lotion (Formulation Example 2)
(1) Alcohol 30.0
(2) Butylene glycol 4.0
(3) Glycerin 2.0
(4) PPG-13 decyltetrades 24 0.3
(5) Octylmethoxycinnamate 0.1
(6) Menthol 0.2
(7) Tocopherol acetate 0.1
(8) Chelating agent Appropriate amount (9) Dye Appropriate amount (10) Essential oil of the present invention 0.01
(11) Purified water residue

Example 3
Emulsion (Formulation Example 1)
(1) Stearic acid 2.0
(2) Cetyl alcohol 1.5
(3) Vaseline 4.0
(4) Squalane 5.0
(5) Glycerol tree 2-ethylhexanoate 2.0
(6) Sorbitan monooleate 2.0
(7) Dipropylene glycol 5.0
(8) PEG 1500 0.3
(9) Triethanolamine 0.1
(10) Preservative appropriate amount (11) Essential oil of the present invention 0.2
(12) Purified water residue

Example 4
Emulsion (Formulation Example 2)
(1) Ethyl alcohol 10.0
(2) Cyclomethicone 0.1
(3) Butylene glycol 5.0
(4) Dimethicone 3.0
(5) Glycene 0.1
(6) Menthol 1.0
(7) Trimethylsiloxysilicic acid 0.1
(8) Caffeine 1.0
(9) Trimethylglycine 1.0
(10) Xanthan gum 0.001
(11) Hydroxyethyl cellulose 0.1
(12) Fermented soybean extract 1.0
(13) Lauryl betaine 0.5
(14) Carbomer 0.2
(15) Chelating agent Appropriate amount (16) Paraben Appropriate amount (17) Benzoic acid Appropriate amount (18) Essential oil of the present invention 0.1
(19) Iron oxide appropriate amount (20) Caustic potash 0.05
(21) Dicalcium glycyrrhizinate 0.01
(22) Pyridoxine hydrochloride 0.01
(23) Ascorbic acid glucoside 0.01
(24) Arbutin 3.0
(25) Yukinoshita extract 0.1
(26) Water residue

Example 5
Emulsion (Formulation Example 3)
(1) Butylene glycol 4.0
(2) Propylene glycol 4.0
(3) Carbomer 0.2
(4) Caustic potash 0.2
(5) Behenic acid 0.5
(6) Stearic acid 0.5
(7) Isostearic acid 0.5
(8) Glyceryl stearate 1.0
(9) Glyceryl isostearate 1.0
(10) Behenyl alcohol 0.5
(11) Squalane 5.0
(12) Trioctanoin 3.0
(13) Phenyltrimethicone 2.0
(14) Batyl alcohol 0.5
(15) Dicalcium glycyrrhizinate 0.01
(16) Preservative appropriate amount (17) Chelating agent appropriate amount (18) Pigment appropriate amount (19) Essential oil of the present invention 0.15
(20) Purified water residue

Example 6
Emulsion (Formulation Example 4)
(1) Glycerol 3.0
(2) Xylitol 2.0
(3) Carbomer 0.1
(4) Caustic potash 0.1
(5) Glyceryl isostearate 1.0
(6) Glyceryl stearate 0.5
(7) Behenyl alcohol 1.0
(8) Batyl alcohol 1.0
(9) Hardened palm oil 2.0
(10) Vaseline 1.0
(11) Squalane 5.0
(12) Erythrityl octoate 3.0
(13) Cyclomethicone 1.0
(14) Preservative appropriate amount (15) Chelating agent appropriate amount (16) Essential oil of the present invention 0.2
(17) Purified water Residual (18) Tranexamic acid 1.0
(19) Pantothenyl ethyl ether 0.5
(20) Nicotinamide 0.1
(21) Trehalose 0.1
(22) Rosemary extract 0.1
(23) Vitamin A 0.1
(24) Ascorbic acid glycoside 0.001
(25) Raspberry extract 1.0
(26) Ogon extract 0.001
(27) Oat extract 0.01

Example 7
Emulsion (Formulation Example 5)
(1) Ethanol 2.0
(2) Cyclomethicone 10.0
(3) Glycerin 5.0
(4) Dibutylene glycol 1.0
(5) Dimethicone 1.0
(6) Cornstarch 4.0
(7) Mineral oil 2.0
(8) Trimethylsiloxysilicic acid 5.0
(9) Polyethylene glycol 3.0
(10) Lactic acid menthyl 0.1
(11) PEG-60 hydrogenated castor oil 1.0
(12) Aminopropyl dimethicone 1.0
(13) Xanthan gum 0.01
(14) Tocopherol acetate 0.01
(15) Caffeine 0.1
(16) Sodium hyaluronate 0.1
(17) Fermented soybean extract 0.01
(18) Hamamelis extract 0.01
(19) Dokudami Extract 0.01
(20) Carbomer 0.3
(21) Matacrylic acid alkyl copolymer 0.2
(22) HEDTA appropriate amount (23) preservative appropriate amount (24) essential oil of the present invention 0.3
(25) Pigment appropriate amount (26) Caustic potash 0.15
(27) Aminomethylpropanol 0.05
(28) Water residue

Example 8
Emulsion (Formulation Example 6)
(1) Ethanol 15.0
(2) Cyclomethicone 6.0
(3) Butylene glycol 0.5
(4) Dimethicone 1.0
(5) Glycerin 1.0
(6) Polyethylene glycol 1.0
(7) Lactic acid menthyl 1.0
(8) Menthol 0.1
(9) Trimethylsiloxysilicic acid 1.0
(10) Caffeine 0.5
(11) Trimethylene glycine 0.1
(12) Xanthan gum 0.1
(13) Hydroxyethyl cellulose 0.1
(14) Fermented soybean extract 0.01
(15) Tocopherol acetate 0.05
(16) Lauryl betaine 0.01
(17) Dehydrated algae extract 0.01
(18) Dokudami extract 0.01
(19) Red algae extract 0.01
(20) Green algae extract 0.01
(21) Cellulose spray 1.0
(22) PEG-60 glyceryl isostearate 1.0
(23) Isostearic acid 1.0
(24) Carbomer 0.1
(25) Alkyl methacrylate alkyl polymer 0.1
(26) EDTA 0.1
(27) Sodium metaphosphate 0.1
(28) Phenoxyethanol 0.2
(29) Paraben 0.2
(30) Essential oil of the present invention 0.45
(31) Iron oxide (red) 0.02
(32) Menthyl glyceryl ether 0.01
(33) Water residue

Example 9
Cream (Formulation Example 1)
(1) Glycerin 10.0
(2) Butylene glycol 5.0
(3) Carbomer 0.1
(4) Caustic potash 0.2
(5) Stearic acid 2.0
(6) Glyceryl stalate 2.0
(7) Glyceryl isostearate 2.0
(8) Vaseline 5.0
(9) Preservative appropriate amount (10) Antioxidant appropriate amount (11) Essential oil of the present invention 0.3
(12) Purified water Residual (13) Chelating agent Appropriate amount (14) Pigment Appropriate amount (15) Stearyl alcohol 2.0
(16) Behenyl alcohol 2.0
(17) Palm hardened oil 2.0
(18) Squalane 10.0
(19) 4-methoxysalicylic acid K 3.0

Example 10
Cream (formulation example 2)
(1) Glycerol 3.0
(2) Dipropylene glycol 7.0
(3) Polyethylene glycol 3.0
(4) Glyceryl stearate 3.0
(5) Glyceryl isostearate 2.0
(6) Stearyl alcohol 2.0
(7) Behenyl alcohol 2.0
(8) Liquid paraffin 7.0
(9) Cyclomethicone 3.0
(10) Dimethicone 1.0
(11) Octyl methoxycinnamate 0.1
(12) Na hyaluronate 0.05
(13) Preservative appropriate amount (14) Antioxidant appropriate amount (15) Essential oil of the present invention 0.4
(16) Purified water Residual (17) Chelating agent appropriate amount (18) Pigment appropriate amount

Example 11
Gel (1) Ethyl alcohol 10.0
(2) Glycerin 5.0
(3) Butylene glycol 5.0
(4) Carbomer 0.5
(5) Aminomethylpropanol 0.3
(6) PEG-60 hydrogenated castor oil 0.3
(7) Menthol 0.02
(8) Preservative appropriate amount (9) Chelating agent appropriate amount (10) Essential oil of the present invention 0.1
(11) Purified water residue

Example 12
Aerosol (Formulation Example 1)
(1) Glycerin 2.0
(2) Dipropylene glycol 2.0
(3) PEG-60 hydrogenated castor oil 0.3
(4) HPCCD 1.0
(5) Preservative appropriate amount (6) chelating agent appropriate amount (7) dye appropriate amount (8) essential oil of the present invention 0.2
(9) Purified water appropriate amount (10) LPG remaining

Example 13
Aerosol (Prescription Example 2)
(1) Alcohol 15.0
(2) Butylene glycol 2.0
(3) Glycerin 1.0
(4) PPG-13 decyltetrades 24 0.1
(5) Silver supported zeolite 1.0
(6) Chelating agent Appropriate amount (7) Dye Appropriate amount (8) Essential oil of the present invention 0.15
(9) Purified water Residual (10) LPG 40.0

Example 14
Aerosol (Prescription Example 3)
(1) Ethanol 60.0
(2) Lactic acid menthyl 0.1
(3) Sodium lactate 0.1
(4) Tocopherol acetate 0.01
(5) Lactic acid 0.01
(6) Caffeine 0.01
(7) Fennel extract 1.0
(8) Hamelis Extract 1.0
(9) Dokudami Extract 1.0
(10) Dipropylene glycol 1.0
(11) Nitrogen gas 0.9
(12) Polyoxyethylene polyoxypropylene 1.0
Decyl tetradecyl ether
(13) Butylene glycol 2.0
(14) Tocopherol 0.05
(15) Essential oil of the present invention 0.1
(16) PEG-60 hydrogenated castor oil 0.1
(17) Water residue

Example 15
Shampoo (1) Lauryl polyethylene (3)
Sulfate sodium salt (30% aqueous solution) 30.0
(2) Sodium lauryl sulfate ester salt (30% aqueous solution) 10.0
(3) Palm oil fatty acid diethanolamide 4.0
(4) Glycerin 1.0
(5) Preservative appropriate amount (6) Essential oil of the present invention 0.5
(7) Dye appropriate amount (8) sequestering agent, pH adjuster appropriate amount (9) purified water residue

Example 16
Rinse (1) Silicone oil 3.0
(2) Liquid paraffin 1.0
(3) Cetyl alcohol 1.5
(4) Stearyl alcohol 1.0
(5) Stearyltrimethylammonium chloride 0.7
(6) Glycerin 3.0
(7) Essential oil of the present invention 0.5
(8) Pigments and preservatives appropriate amount (9) Purified water residue

Example 17
Body shampoo (1) Lauric acid 2.5
(2) Myristic acid 5.0
(3) Palmitic acid 2.5
(4) Oleic acid 2.5
(5) Cocoyl diethanolamide 1.0
(6) Glycerin 20.0
(7) Caustic potash 3.6
(8) Dye proper amount (9) Essential oil of the present invention 0.5
(10) metal ion sequestering agent appropriate amount (11) purified water residue

Example 18
Fragrance (1) Alcohol 75.0
(2) Purified water Residual (3) Dipropylene glycol 5.0
(4) Essential oil of the present invention 10.0
(5) Antioxidant 8.0
(6) Appropriate amount of dye (7) Appropriate amount of UV absorber

Here, the “fragrance” is obtained by dissolving the essential oil of the present invention in alcohol (for example, ethyl alcohol) or aqueous alcohol. The fragrance contains 1% to 99% by mass of the essential oil of the present invention. The mixing ratio of water and alcohol is in the range of 50:50 to 0: 100. Fragrances can contain solubilizers, softeners, fumestanes, thickeners, bacteriostats, or other materials commonly used in cosmetics.

Example 19
Room Fragrance (1) Alcohol 80.0
(2) Purified water Residue (3) Antioxidant 5.0
(4) Essential oil of the present invention 3.0
(5) 3-Methyl-3-methoxybutanol 5.0
(6) Dibenzylidenesorbitol 5.0

Example 20
Incense (1) Tab powder 75.5
(2) Sodium benzoate 15.5
(3) Essential oil of the present invention 5.0
(4) Eucalyptus oil 1.0
(5) Fennel oil 1.0
(6) Purified water residue

Example 21
Bath salt (1) Sodium sulfate 45.0
(2) Sodium bicarbonate 45.0
(3) Hyssop oil 9.0
(4) Essential oil of the present invention 1.0

Example 22
Massage Gel (1) Erythritol 2.0
(2) Caffeine 5.0
(3) Oat extract 3.0
(4) Glycerin 50.0
(5) Carboxyvinyl polymer 0.4
(6) Polyethylene glycol 400 30.0
(7) edet trisodium 0.1
(8) Polyoxylene (10) Methyl polysiloxane copolymer 2.0
(9) Squalane 1.0
(10) Potassium hydroxide 0.15
(11) Essential oil of the present invention 1.0

Example 23
Massage cream (1) Solid paraffin 5.0
(2) Beeswax 10.0
(3) Vaseline 15.0
(4) Liquid paraffin 41.0
(5) 1.3-butylene glycol 4.0
(6) Glycerol monostearate 2.0
(7) POE (20) sorbitan monolaurate 2.0
(8) Borax 0.2
(9) Caffeine 2.0
(10) Preservative appropriate amount (11) Antioxidant appropriate amount (12) Essential oil of the present invention 1.0
(13) Purified water residue

Example 24
Aromatic fiber A microcapsule (particle diameter of 50 μm or less, occupying a microcapsule) containing the essential oil of the present invention in a cuproammonium cellulose solution (cellulose concentration 10% by weight, ammonium concentration 7% by weight, copper concentration 3.6% by weight) Is added within a range of 0.1 to 20% by weight of cellulose based on the weight of cellulose, mixed, then spun in accordance with a normal wet spinning method, passed through a refining step and a drying step, and then an aromatic fiber. Got.

Example 25
Granule (1) Sucralose 0.1
(2) Essential oil of the present invention 0.1
(3) Flavoring 5.0
(4) Excipient (Theolus) 10.0
(5) Maltitol residual

Example 26
Tablet (chewable type)
Inositol 11.0
Maltitol 21.0
Sucrose 0.5
White coconut extract (DNA Na) 0.1
Yeast extract 0.1
Essential oil of the present invention 0.1
Flavoring 5.0
Excipient residue

Example 27
Tablet lubricant (sucrose fatty acid ester, etc.) 1.0
Gum arabic aqueous solution (5%) 2.0
Acidulant 1.0
Appropriate amount of coloring agent Essential oil of the present invention 0.1
Carbohydrate (such as powdered sugar or sorbitol)

Example 28
Candy sugar 50.0
Minamata 47.95
Organic acid 2.0
Essential oil of the present invention 0.05

Example 29
Gum sugar 43.0
Gum base 30.95
Glucose 10.0
Minamata 16.0
Essential oil of the present invention 0.05

  The skin external preparations, miscellaneous goods, clothes or foods of these examples are subjected to use tests in typical usage forms of the respective product forms, and general malaise, hot flashes, coldness due to insufficient estrogen secretion or hormonal imbalance. Various symptoms such as irritability and anxiety can be improved.

Graph showing estrogenic action of essential oils Graph showing that the action of essential oil is mediated by estrogen receptor

Claims (2)

An estrogen-like agent that acts via an estrogen receptor, containing near uri oil as an active ingredient . A cosmetic method (excluding medical practice) that enhances the estrogen-like action via the estrogen receptor by smelling the smell of near-uri oil or by applying near-uri oil to the skin.

Images